Skip to content

Ultragenyx Pharmaceutical

US · RARE #3012 by market cap Listed 1970
16.48 -0.74 -4.30%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:31

Quant vs Street three independent views, side by side

StockVane factor grade
D-
Momentum strategy signal
Strong Sell
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

✦ Quant Analyst Revision Trend how this is computed

Deteriorating
8
■ Upgrades■ Downgrades
  • 0 upgrades vs 8 downgrades among tracked analyst rating changes.
  • Most recent: RBC Capital moved from Buy to Hold on 2026-10-08.

Analyst consensus 19 analysts

Buy
Avg price target 25.39 +54.1%
Price target rangecurrent 16.48
Low16.00
Avg25.39
High39.00
Buy 47% Hold 53% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-06 Citi -- Buy 22.00
2026-11-06 H.C. Wainwright -- Buy 25.00
2026-11-05 Piper Sandler -- Buy 36.00
2026-11-05 Citi -- Buy 22.00
2026-11-05 Leerink Partners -- Buy 33.00
2026-11-05 H.C. Wainwright -- Buy 25.00
2026-11-05 Barclays -- Buy 32.00
2026-11-04 TD Cowen -- Buy 19.00
2026-11-04 CCORF -- Buy 34.00
2026-11-04 BofA Securities -- Hold 20.00
2026-11-04 Wedbush -- Hold 22.00
2026-11-04 Morgan Stanley -- Hold 22.00
2026-11-04 Goldman Sachs -- Hold 17.00
2026-11-04 RBC Capital -- Hold 19.00
2026-11-03 Cantor Fitzgerald -- Buy 39.00
2026-11-03 Wells Fargo -- Hold 19.00
2026-11-03 BofA Securities -- Hold 20.00
2026-10-21 Piper Sandler -- Buy 36.00
2026-10-15 UBS -- Hold 16.00
2026-10-15 H.C. Wainwright -- Buy 25.00
2026-10-14 UBS -- Hold 16.00
2026-10-14 H.C. Wainwright -- Buy 25.00
2026-10-09 BofA Securities -- Hold 20.00
2026-10-08 H.C. Wainwright -- Buy 25.00
2026-10-08 RBC Capital -- Hold 19.00

Price target trend monthly average, last 3 years

Recent rating changes

DateFirmChangeTarget
2026-10-08 RBC Capital Buy → Hold 19.00
2026-09-21 Evercore Buy → Hold 18.00
2026-09-18 Morgan Stanley Buy → Hold 20.00
2026-09-18 Wells Fargo Buy → Hold 18.00
2026-09-18 BofA Securities Buy → Hold 20.00
2026-09-03 J.P. Morgan Buy → Hold 36.00
2026-09-02 William Blair Buy → Hold --
2026-03-24 Goldman Sachs Buy → Hold 25.00

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-03 After close ±6.76% +3.19% (in line)
2026/Q2 2026-08-04 After close ±19.62% -3.41% (in line)
2026/Q1 2026-05-05 After close ±8.84% +3.68% (in line)
2025/Q4 2026-02-12 After close ±8.40% -12.68% (beat)
2025/Q3 2025-11-04 After close ±11.35% -1.82% (in line)
2025/Q2 2025-08-05 After close ±9.32% -3.01% (in line)
2025/Q1 2025-05-06 After close ±18.50% -4.68% (in line)
2024/Q4 2025-02-13 After close ±13.82% -2.37% (in line)
2024/Q3 2024-11-05 After close ±13.99% -3.18% (in line)
2024/Q2 2024-08-01 After close ±11.60% +14.31% (beat)
2024/Q1 2024-05-02 After close ±9.84% -1.04% (in line)
2023/Q4 2024-02-15 After close ±15.02% +5.75% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 19:31:44 · For reference only, not investment advice and not tailored to your situation.

Ultragenyx Pharmaceutical discussion 0 comments

Add a comment